Enzomenib, an oral, small-molecule inhibitor designed to disrupt the menin-MLL protein interaction involved in leukemogenesis
GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Subscribe To Our Newsletter & Stay Updated
